Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer

NCT01307631 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

37

Enrollment

NIH

Sponsor class

Conditions

Endometrial Adenocarcinoma
Endometrial Adenosquamous Carcinoma
Endometrial Clear Cell Adenocarcinoma
Endometrial Serous Adenocarcinoma
Recurrent Uterine Corpus Carcinoma

Interventions

DRUG: Akt Inhibitor MK2206
OTHER: Laboratory Biomarker Analysis

Sponsor

National Cancer Institute (NCI)